TITLE

Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis

AUTHOR(S)
Miyamae, Takako; Sano, Fumie; Ozawa, Remi; Imagawa, Tomoyuki; Inayama, Yoshiaki; Yokota, Shumpei
PUB. DATE
January 2010
SOURCE
Pediatric Rheumatology;2010, Vol. 8, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We report a 14-year-old girl with juvenile dermatomyositis (JDM) complicated by severe inflammatory calcinosis successfully treated with thalidomide. She was diagnosed as JDM when she was 4 years old after a few months of increasing lethargy, muscle pain, muscle weakness, and rash. During three months, clinical manifestations and abnormal laboratory findings were effectively treated with oral prednisolone. However, calcinosis was recognized 18 months after disease onset. Generalized calcinosis rapidly progressed with high fever, multiple skin/subcutaneous inflammatory lesions, and increased level of CRP. Fifty mg/day (1.3 mg/kg day) of oral thalidomide was given for the first four weeks, and then the dose was increased to 75 mg/day. Clinical manifestations subsided, and inflammatory markers had clearly improved. Frequent high fever and local severe pain with calcinosis were suppressed. The levels of FDP-E, IgG, and tryglyceride, which were all elevated before the thalidomide treatment, were gradually returned to the normal range. Over the 18 months of observation up to the present, she has had no inflammatory calcinosis, or needed any hospitalization, although established calcium deposits still remain. Her condition became painless, less extensive and less inflammatory with the CRP level below 3.08 mg/dL. Recent examination by whole-body 18F-FDG-PET-CT over the 15 months of thalidomide treatment demonstrated fewer hot spots around the subcutaneous calcified lesions.
ACCESSION #
48460043

 

Related Articles

  • IgG Oligosaccharide Alterations Are a Novel Diagnostic Marker for Disease Activity and the Clinical Course of Inflammatory Bowel Disease. Shinzaki, Shinichiro; Iijima, Hideki; Nakagawa, Takatoshi; Egawa, Satoshi; Nakajima, Sachiko; Ishii, Shuji; Irie, Takanobu; Kakiuchi, Yoshimi; Nishida, Tsutomu; Yasumaru, Masakazu; Kanto, Tatsuya; Tsujii, Masahiko; Tsuji, Shingo; Mizushima, Tsunekazu; Yoshihara, Harumasa; Kondo, Akihiro; Miyoshi, Eiji; Hayashi, Norio // American Journal of Gastroenterology;May2008, Vol. 103 Issue 5, p1173 

    BACKGROUND AND AIMS: Patients with inflammatory bowel disease (IBD) share several immunologic similarities with rheumatoid arthritis (RA). Patients with RA have significantly increased levels of serum agalactosyl immunoglobulin G (IgG). Our aim was to investigate the clinical significance of...

  • Assessment of Thrombophilic Abnormalities During the Active State of Inflammatory Bowel Disease. Maher, Maha M.; Soloma, Somaya H. // Saudi Journal of Gastroenterology;Oct2008, Vol. 14 Issue 4, p192 

    Background/Aims: Thromboembolic disease has been recognized as a complication of inflammatory bowel disease (IBD). The relative contributions of inherited or acquired thrombophilia and the inflammatory response to the mechanism of this tendency are unclear. Thrombotic events are more common in...

  • Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Balzola, Federico; Bernstein, Charles; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2011, Vol. 12 Issue 2, p66 

    The article presents a study on acute severe reactions of inflammatory bowel disease (IBD) patients to infliximab. The role of anti-infliximab antibodies and other possible risk factors, such as episodic treatment and age, for acute severe reactions were examined. The study shows that the...

  • Continuing Medical Education Questions: April 2011. DeVault, Kenneth R.; Coe, Susan; Yize Wang // American Journal of Gastroenterology;Apr2011, Vol. 106 Issue 4, p660 

    A quiz concerning the effectiveness of biological therapies for inflammatory bowel diseases is presented.

  • Continuing Medical Education Questions: April 2011. DeVault, Kenneth R.; Khanna, Reena; Win, Lay Lay // American Journal of Gastroenterology;Apr2011, Vol. 106 Issue 4, p600 

    A quiz concerning inflammatory bowel diseases (IBD)and the effectiveness of various therapy for IBD is presented.

  • Not one but two inflammatory bowel disease susceptibility loci map to chromosome 16. Adeniji, Olaitan A.; Mrug, Michal M.; DiPalma, Jack A. // American Journal of Gastroenterology;Sep2002, Vol. 97 Issue 9, p2464 

    The association of NOD2 gene mutations with inflammatory bowel disease (IBD) has been reported by multiple research groups. In this high-density linkage experiment using 39 microsatellite markers, Hampe et al. observed a triple-peaked configuration of the linkage curve with peak logarithm of...

  • New serological biomarkers of inflammatory bowel disease. Xuhang Li; Conklin, Laurie; Alex, Philip; Mizoguchi, Emiko // World Journal of Gastroenterology;9/7/2008, Vol. 14 Issue 33, p5115 

    Serological biomarkers in inflammatory bowel disease (IBD) are a rapidly expanding list of non-invasive tests for objective assessments of disease activity, early diagnosis, prognosis evaluation and surveillance. This review summarizes both old and new biomarkers in IBD, but focuses on the...

  • Personalized Medicine in Inflammatory Bowel Disease. McGovern, Dermot // Gastroenterology & Hepatology;Oct2014, Vol. 10 Issue 10, p662 

    An interview with Dr. Dermot McGovern, Director, Translated Medicine and Professor of Medicine, Inflammatory Bowel Disease Center and Immunobiology Research Institute, California is presented. Topics covered include the definition of personalized medicine as customized healthcare, the genetic...

  • Serologic Markers in Inflammatory Bowel Disease (IBD). Nakamura, Robert M.; Barry, Mary // MLO: Medical Laboratory Observer;Nov2001, Vol. 33 Issue 11, p8 

    Presents information on inflammatory bowel disease (IBD). Difference between IBD and irritable bowel syndrome; Serum immune markers that are useful in the diagnosis and management of irritable bowel syndrome; Types and limitations of methods used in the detection and quantification of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics